A pathogenic mechanism leading to partial lipodistrophy and prospects for pharmacological treatment of insulin resistance syndrome

Nadir M. Maraldi, Cristina Capanni, Elisabetta Mattioli, Marta Columbaro, Stefano Squarzoni, Weena K. Parnaik, Manfred Wehnert, Giovanna Lattanzi

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

The understanding of a common complex phenotype such as insulin resistance can be favoured by evaluation of monogenic syndromes. Clinical definition, pathogenesis, and therapeutical strategies for the insulin resistance syndrome can thus be improved by the characterization at the molecular genetic level of monogenic forms of lipodystrophies. Here we report experimental evidence on the pathogenic mechanism underlying insulin resistance in a rare form of laminopathy, due to mutation of the LMNA gene coding for lamin A/C, the Dunning-type familial partial lipodystrophy (FPLD). The defect, consisting in the intranuclear accumulation of mutant unprocessed precursors of lamin A, reduces the amount of the DNA-bound adipocyte transcription factor sterol regulatory element binding protein 1 (SREBP1) and lowers the peroxisome proliferator-activated receptor (PPARγ) expression, causing the impairment of pre-adipocyte differentiation. The treatment with the PPARγ ligand troglitazone (TDZ) is able to rescue the adipogenic program. Since FPLD recapitulates the essential metabolic abnormalities of the common insulin resistance syndrome, the beneficial effects of TDZ on monogenic lipodystrophies might provide a clue as to the future treatment strategies also for the common syndrome of insulin resistance. (www.actabiomedica.it).

Original languageEnglish
Pages (from-to)207-215
Number of pages9
JournalActa Biomedica
Volume78
Issue numberSUPPL. 1
Publication statusPublished - Apr 2007

Fingerprint

Insulin Resistance
Pharmacology
Familial Partial Lipodystrophy
Lipodystrophy
Peroxisome Proliferator-Activated Receptors
troglitazone
Adipocytes
Lamin Type A
Sterol Regulatory Element Binding Protein 1
Therapeutics
Molecular Biology
Transcription Factors
Ligands
Phenotype
Mutation
DNA
Genes

Keywords

  • Adipocyte
  • Chromatin
  • Drug treatment
  • FPLD
  • Insulin resistance
  • Lamin A/C
  • Laminopathies
  • Lipodystrophy
  • lMNA gene
  • Pathogenic mechanisms
  • PPARg
  • SREBP1

ASJC Scopus subject areas

  • Medicine(all)

Cite this

A pathogenic mechanism leading to partial lipodistrophy and prospects for pharmacological treatment of insulin resistance syndrome. / Maraldi, Nadir M.; Capanni, Cristina; Mattioli, Elisabetta; Columbaro, Marta; Squarzoni, Stefano; Parnaik, Weena K.; Wehnert, Manfred; Lattanzi, Giovanna.

In: Acta Biomedica, Vol. 78, No. SUPPL. 1, 04.2007, p. 207-215.

Research output: Contribution to journalArticle

Maraldi, Nadir M. ; Capanni, Cristina ; Mattioli, Elisabetta ; Columbaro, Marta ; Squarzoni, Stefano ; Parnaik, Weena K. ; Wehnert, Manfred ; Lattanzi, Giovanna. / A pathogenic mechanism leading to partial lipodistrophy and prospects for pharmacological treatment of insulin resistance syndrome. In: Acta Biomedica. 2007 ; Vol. 78, No. SUPPL. 1. pp. 207-215.
@article{375b246d92cc4572abac1b7fa7a74674,
title = "A pathogenic mechanism leading to partial lipodistrophy and prospects for pharmacological treatment of insulin resistance syndrome",
abstract = "The understanding of a common complex phenotype such as insulin resistance can be favoured by evaluation of monogenic syndromes. Clinical definition, pathogenesis, and therapeutical strategies for the insulin resistance syndrome can thus be improved by the characterization at the molecular genetic level of monogenic forms of lipodystrophies. Here we report experimental evidence on the pathogenic mechanism underlying insulin resistance in a rare form of laminopathy, due to mutation of the LMNA gene coding for lamin A/C, the Dunning-type familial partial lipodystrophy (FPLD). The defect, consisting in the intranuclear accumulation of mutant unprocessed precursors of lamin A, reduces the amount of the DNA-bound adipocyte transcription factor sterol regulatory element binding protein 1 (SREBP1) and lowers the peroxisome proliferator-activated receptor (PPARγ) expression, causing the impairment of pre-adipocyte differentiation. The treatment with the PPARγ ligand troglitazone (TDZ) is able to rescue the adipogenic program. Since FPLD recapitulates the essential metabolic abnormalities of the common insulin resistance syndrome, the beneficial effects of TDZ on monogenic lipodystrophies might provide a clue as to the future treatment strategies also for the common syndrome of insulin resistance. (www.actabiomedica.it).",
keywords = "Adipocyte, Chromatin, Drug treatment, FPLD, Insulin resistance, Lamin A/C, Laminopathies, Lipodystrophy, lMNA gene, Pathogenic mechanisms, PPARg, SREBP1",
author = "Maraldi, {Nadir M.} and Cristina Capanni and Elisabetta Mattioli and Marta Columbaro and Stefano Squarzoni and Parnaik, {Weena K.} and Manfred Wehnert and Giovanna Lattanzi",
year = "2007",
month = "4",
language = "English",
volume = "78",
pages = "207--215",
journal = "Acta Biomedica de l'Ateneo Parmense",
issn = "0392-4203",
publisher = "L'Ateneo Parmense",
number = "SUPPL. 1",

}

TY - JOUR

T1 - A pathogenic mechanism leading to partial lipodistrophy and prospects for pharmacological treatment of insulin resistance syndrome

AU - Maraldi, Nadir M.

AU - Capanni, Cristina

AU - Mattioli, Elisabetta

AU - Columbaro, Marta

AU - Squarzoni, Stefano

AU - Parnaik, Weena K.

AU - Wehnert, Manfred

AU - Lattanzi, Giovanna

PY - 2007/4

Y1 - 2007/4

N2 - The understanding of a common complex phenotype such as insulin resistance can be favoured by evaluation of monogenic syndromes. Clinical definition, pathogenesis, and therapeutical strategies for the insulin resistance syndrome can thus be improved by the characterization at the molecular genetic level of monogenic forms of lipodystrophies. Here we report experimental evidence on the pathogenic mechanism underlying insulin resistance in a rare form of laminopathy, due to mutation of the LMNA gene coding for lamin A/C, the Dunning-type familial partial lipodystrophy (FPLD). The defect, consisting in the intranuclear accumulation of mutant unprocessed precursors of lamin A, reduces the amount of the DNA-bound adipocyte transcription factor sterol regulatory element binding protein 1 (SREBP1) and lowers the peroxisome proliferator-activated receptor (PPARγ) expression, causing the impairment of pre-adipocyte differentiation. The treatment with the PPARγ ligand troglitazone (TDZ) is able to rescue the adipogenic program. Since FPLD recapitulates the essential metabolic abnormalities of the common insulin resistance syndrome, the beneficial effects of TDZ on monogenic lipodystrophies might provide a clue as to the future treatment strategies also for the common syndrome of insulin resistance. (www.actabiomedica.it).

AB - The understanding of a common complex phenotype such as insulin resistance can be favoured by evaluation of monogenic syndromes. Clinical definition, pathogenesis, and therapeutical strategies for the insulin resistance syndrome can thus be improved by the characterization at the molecular genetic level of monogenic forms of lipodystrophies. Here we report experimental evidence on the pathogenic mechanism underlying insulin resistance in a rare form of laminopathy, due to mutation of the LMNA gene coding for lamin A/C, the Dunning-type familial partial lipodystrophy (FPLD). The defect, consisting in the intranuclear accumulation of mutant unprocessed precursors of lamin A, reduces the amount of the DNA-bound adipocyte transcription factor sterol regulatory element binding protein 1 (SREBP1) and lowers the peroxisome proliferator-activated receptor (PPARγ) expression, causing the impairment of pre-adipocyte differentiation. The treatment with the PPARγ ligand troglitazone (TDZ) is able to rescue the adipogenic program. Since FPLD recapitulates the essential metabolic abnormalities of the common insulin resistance syndrome, the beneficial effects of TDZ on monogenic lipodystrophies might provide a clue as to the future treatment strategies also for the common syndrome of insulin resistance. (www.actabiomedica.it).

KW - Adipocyte

KW - Chromatin

KW - Drug treatment

KW - FPLD

KW - Insulin resistance

KW - Lamin A/C

KW - Laminopathies

KW - Lipodystrophy

KW - lMNA gene

KW - Pathogenic mechanisms

KW - PPARg

KW - SREBP1

UR - http://www.scopus.com/inward/record.url?scp=34347218964&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34347218964&partnerID=8YFLogxK

M3 - Article

C2 - 17465333

AN - SCOPUS:34347218964

VL - 78

SP - 207

EP - 215

JO - Acta Biomedica de l'Ateneo Parmense

JF - Acta Biomedica de l'Ateneo Parmense

SN - 0392-4203

IS - SUPPL. 1

ER -